Parkinson's Disease News and Research

Latest Parkinson's Disease News and Research

New quantitative methods to detect small signs of tremor

Sensitive new quantitive methods could be used to detect small signs of increased tremor and impaired motor skills caused by exposure to certain metals, and to follow up the treatment of neurological disorders, reveals a thesis from the University of Gothenburg, Sweden.

4 Oct 2010

Scientists discover c-Abl protein role in Parkinson's disease progression

Johns Hopkins scientists have discovered that the over-activation of a single protein may shut down the brain-protecting effects of a molecule and facilitate the most common form of Parkinson's disease.

4 Oct 2010

Advances in treatment and management of neurological disorders

The latest advances in treating neurologic disorders such as stroke, headache, Parkinson's disease, epilepsy and sleep disorders are detailed in a special issue of the journal Neurologic Clinics.

4 Oct 2010

USFDA grants Sun Pharma tentative approval for generic Stalevo ANDA

Sun Pharmaceutical Industries Ltd. announced that USFDA has granted its subsidiary a tentative approval for its Abbreviated New Drug Application (ANDA) to market a generic version of Orion's Stalevo® tablets.

1 Oct 2010

Cortex regains global rights to AMPAKINE compounds for treatment of schizophrenia and depression

Cortex Pharmaceuticals, Inc. announced that it has regained worldwide rights to develop and commercialize its AMPAKINE® compounds for the treatment of schizophrenia and depression.

1 Oct 2010

Intra-Cellular Therapies demonstrates ability of ITI-002 to improve motor and non-motor behaviors in PD

Intra-Cellular Therapies, Inc. today announced results from studies demonstrating the anti-Parkinson and other beneficial effects of ITI-002 (IC200214), the Company's novel and selective phosphodiesterase type I (PDE1) inhibitor.

1 Oct 2010

Neurologic Clinics journal publishes latest advances in neurologic disorders

The latest advances in treating neurologic disorders such as stroke, headache, Parkinson's disease, epilepsy and sleep disorders are detailed in a special issue of the journal Neurologic Clinics.

1 Oct 2010

Universitat Jaume I evaluates ruthenium compounds for neurodegenerative disease treatment

The pharmaceutical division of the company Neuron BPh and the research group of Organometallic Chemistry and Homogeneous Catalysis of the Universitat Jaume I, have evaluated the possible applications of a series of ruthenium compounds for their future use in the treatment of neurodegenerative disease such as Alzheimer.

30 Sep 2010

Penn Medicine selected as study site for PPMI

The Penn Medicine Parkinson's Disease and Movement Disorders Center announced that it is one of 18 official study sites for the Parkinson's Progression Markers Initiative (PPMI), a landmark observational clinical study sponsored by The Michael J. Fox Foundation, which will use a combination of advanced imaging, biologics sampling and behavioral assessments to identify biomarkers of Parkinson's disease progression.

30 Sep 2010

McLean Researchers receive award to create first clinic-ready human induced iPS cells

Belmont, MA-Researchers at Harvard Affiliated McLean Hospital have been awarded a $1.9 million National Institutes of Health Director's Opportunity Award to continue their research into creating human induced pluripotent (iPS) stem cells using a method aimed at eliminating the risk of cancer and other problems associated with other options such as genome-integrating viral methods.

30 Sep 2010

COE on Brain Aging at NYU Langone establishes Lewy Body Disease Center

The Center of Excellence (COE) on Brain Aging at NYU Langone Medical Center has established a specialty center for the diagnosis and treatment of Lewy Body Disease, a multi-system disease involving disturbances of cognition, behavior, sleep and autonomic function. Lewy Body Disease, or LBD, affects an estimated 1.3 million individuals in the United States and is widely misdiagnosed because LBD symptoms closely resemble those of other more commonly known diseases such as Alzheimer's and Parkinson's disease.

30 Sep 2010

NINDS establishes new sites as part of Morris K. Udall Centers of Excellence in Parkinson's Disease Research

The National Institute of Neurological Disorders and Stroke (NINDS), a component of the National Institutes of Health, has established two new sites as part of the Morris K. Udall Centers of Excellence in Parkinson's Disease Research. The NINDS grants will provide a five-year investment totaling more than $16 million for Emory University in Atlanta and the Feinstein Institute for Medical Research in Manhasset, N.Y.

29 Sep 2010

Synosia's SYN-118 HPPD inhibitor beneficial for Parkinson's patients: Study

Synosia Therapeutics today announced the first clinical study results showing that SYN-118 provides clinically meaningful benefits to Parkinson's patients, has a good safety profile and is well tolerated. Results from an open-label, proof-of-mechanism study of SYN-118 (CL02) were presented at the World Parkinson Congress in Glasgow, Scotland.

29 Sep 2010

Brain cells outside damaged area in stroke patients take on new roles

The world's largest study using neuroimaging of stroke patients struggling to regain ability to communicate finds that brain cells outside the damaged area can take on new roles.

29 Sep 2010

XenoPort to present XP21279 clinical trial data at World Parkinson Congress meeting

XenoPort, Inc. announced today that new data from its first clinical trial of XP21279, a Transported Prodrug of L-Dopa, in Parkinson's disease patients will be presented at the upcoming World Parkinson Congress meeting in Glasgow, Scotland.

29 Sep 2010

Study indicates majority of children suffering from chronic headache may outgrow the condition

Most children who suffer from chronic daily headache may outgrow the disabling condition, according to research published in the July 15, 2009, online issue of NeurologyÂ®, the medical journal of the American Academy of Neurology.

28 Sep 2010

Higher education levels increases need for symptomatic control of Parkinson's disease

Individuals who have higher levels of education and who are more impaired by Parkinson's disease appear to require treatment for their symptoms earlier than do other patients, according to a report posted online today that will appear in the September print issue of Archives of Neurology, one of the JAMA/Archives journals.

28 Sep 2010

Michael J. Fox Foundation launches PPMI clinical study to identify Parkinson's disease biomarkers

The Michael J. Fox Foundation has launched the Parkinson's Progression Markers Initiative (PPMI), the first ever large scale clinical study exclusively focused on identifying and validating Parkinson's disease biomarkers.

28 Sep 2010

People with Parkinson's disease have high levels of beta-HCH pesticide

People with Parkinson's disease have significantly higher blood levels of a particular pesticide than healthy people or those with Alzheimer's disease, researchers at UT Southwestern Medical Center have found.

27 Sep 2010

Alzheimer's treatments may prove effective if started in middle-aged people: Study

Memory lapses that occur with normal aging are a source of worry for many who fear Alzheimer's disease. Now a new Mayo Clinic-led study published in the July 16 issue of the New England Journal of Medicine suggests that the carriers of a common genetic risk factor for Alzheimer's disease begin to have memory declines in their mid-50s, far earlier than previously thought.

27 Sep 2010

Parkinson's Disease News and Research

Latest Parkinson's Disease News and Research

New quantitative methods to detect small signs of tremor

Scientists discover c-Abl protein role in Parkinson's disease progression

Advances in treatment and management of neurological disorders

USFDA grants Sun Pharma tentative approval for generic Stalevo ANDA

Cortex regains global rights to AMPAKINE compounds for treatment of schizophrenia and depression

Intra-Cellular Therapies demonstrates ability of ITI-002 to improve motor and non-motor behaviors in PD

Neurologic Clinics journal publishes latest advances in neurologic disorders

Universitat Jaume I evaluates ruthenium compounds for neurodegenerative disease treatment

Penn Medicine selected as study site for PPMI

McLean Researchers receive award to create first clinic-ready human induced iPS cells

COE on Brain Aging at NYU Langone establishes Lewy Body Disease Center

NINDS establishes new sites as part of Morris K. Udall Centers of Excellence in Parkinson's Disease Research

Synosia's SYN-118 HPPD inhibitor beneficial for Parkinson's patients: Study

Brain cells outside damaged area in stroke patients take on new roles

XenoPort to present XP21279 clinical trial data at World Parkinson Congress meeting

Study indicates majority of children suffering from chronic headache may outgrow the condition

Higher education levels increases need for symptomatic control of Parkinson's disease

Michael J. Fox Foundation launches PPMI clinical study to identify Parkinson's disease biomarkers

People with Parkinson's disease have high levels of beta-HCH pesticide

Alzheimer's treatments may prove effective if started in middle-aged people: Study

Human iPSCs: A Full Guide to Advanced in Vitro Models and Applications eBook

The future of automation: Machine learning–driven hepatocyte and organoid counting

From street to lab: Advancing controlled substance testing with handheld Raman and FTIR

Reimagining light scattering for biotherapeutics

Parkinson's Disease News and Research

Latest Parkinson's Disease News and Research

Human iPSCs: A Full Guide to Advanced in Vitro Models and Applications eBook

The future of automation: Machine learning–driven hepatocyte and organoid counting

From street to lab: Advancing controlled substance testing with handheld Raman and FTIR

Reimagining light scattering for biotherapeutics

Newsletters you may be interested in